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In the previous paper of ours we compared, prior to start any treatment, a number of immunological parameters in 24 chronic
myeloid leukemia patients with the same number of healthy subjects matched by age and sex. We found signiﬁcant diﬀerences
in the levels of immunoglobulins, the C4 component of complement, the C-reactive protein, interleukin 6, the composition of
lymphocyte population and the production of some cytokines by stimulated CD3+ cells. Eleven of these patients were followed
longitudinally. After treatment with hydroxyurea, interferon alpha, imatinib mesylate and dasatinib, or various combinations
thereof, hematological remission was achieved in all patients and complete cytogenetic remission in nine of them. There was
a nearly general tendency towards normalization of the abnormalities observed in the patients at their enrollment.
1.Introduction
The treatment of chronic myeloid leukemia (CML) now
oﬀers several options from which to choose. Hydroxyurea
(HU) was introduced in the late 1960s and for decades
remained the mainstay of palliation in CML. However,
HU does not induce cytogenetic remissions in a signiﬁcant
percentage of patients nor does it markedly change the
natural history of the disease. The adverse eﬀects include
gastrointestinal problems and cutaneous defects as leg ulcers
[1],hyperpigmentationoftheskinandnails,alichenplanus-
like eruption, lupus erythematosus, and dermatomyositis-
like eruption [2]. The ﬁrst observational reports on a cytore-
ductive eﬀect of interferon α (IFNα) in CML patients date
back to 1980s, when IFNα treatment was introduced at
the M.D. Anderson Cancer Center, Houston, Texas [3, 4].
IFNα induces durable major and even complete cytogenetic
remissions (CCR) persisting for months, sometimes even for
years [5]. IFNα not only mediates antileukemic responses via
induction of T-cell immunity [6, 7], but it also promotes
humoral immunity against CML antigens [8]. Some param-
eters of innate immunity, which apparently plays a role in
anticancer immunity, are also favorably inﬂuenced by IFNα
[9,10].ThismightelucidatetheeﬃcacyofIFNαtreatmentin
vivo by orchestrating a network of immune cells rather than
by the activation of individual populations. Other mecha-
nisms involved in modulating the course of the disease by
IFNαareconnectedwithitsantiproliferativeeﬀect.However,
long-term treatment with IFNα can also produce or exac-
erbate immune-mediated complications [11, 12], such as2 Clinical and Developmental Immunology
cutaneous vasculitis, hemolytic anemia, thyroid gland disor-
ders, immune-mediated thrombocytopenia, nephrotoxicity,
pemphigus foliaceus, rheumatoid arthritis, systemic lupus
erythematosus, and even heart dysfunction based probably
on immune mechanisms [11]. A revolution into therapy of
CML has been brought by the introduction of the so-called
targeted drugs. The ﬁrst of these disease-tailored products
has been imatinib mesylate (IM) which blocks the ATP-
binding pocket on the BCR-ABL tyrosine-kinase and thus
prevents the activation of this enzyme which plays the key
role in the pathogenesis of CML [13]. IM has been reported
to have induced CCR in 74% of the newly diagnosed patients
and is also active in patients previously treated with INFα
[14]. According to a recent update, a ﬁve-year survival has
been achieved in nearly 90% of CML patients [15]. However,
in a portion of patients, resistance to the drug develops
mostly due to the mutations in the enzyme catalytic domain
[16] or as a consequence of the ampliﬁcation of the bcr-
abl fusion gene [17]. To deal with the problem, a new
generation of targeted drugs is being introduced and some
of its representatives are already in clinical use, for example,
dasatinib [18] or nilotinib [19].
Still, neither of these drugs can cure the disease most
probably due to their failure to hit the quiescent cancer
stem cells. When the treatment is interrupted, the disease
relapses. Many oncohematologists believe that the problem
of curing CML might be unriddled by supplementing
the chemotherapy with immunotherapeutic approaches. A
mathematical model has been constructed suggesting that
immunotherapeutic intervention tailored to the clinical
condition and the underlying immune status of the patient
m a yr e s u l ti nt h ec u r eo fC M L[ 20].
Although the role of immune reactions in the course
of CML has been demonstrated beyond reasonable doubt,
the ﬁrst vaccine trials reported in the past 10 years have
not been particularly successful (for review see [21]). We
are of the opinion that to achieve the immunization goal it
will be necessary to augment our present knowledge on the
immunology of CML patients and that very likely this will
lead to appreciable progress in the future immunotherapeu-
tic undertakings.
It was the purpose of the present study to construct
immunological proﬁles of CML patients by testing several
parameters of their innate immunity early after diagnosis,
that is, prior to the start of any therapy and then to
follow the inﬂuence of diﬀerent therapeutic regimens on
these parameters and the association of their changes with
the clinical condition. In a previous paper of ours [22],
representing the ﬁrst part of the present study, we reported
the ﬁndings obtained in 24 CML patients before the start
of any therapy and in the same number of matched healthy
subjects. We found a number of deviations from the norm in
the immune reactivity of CML patients and signiﬁcant dif-
ferences between the patients’ and control groups. The main
diﬀerences encountered in the patients were represented by
increased levels of IgA (P<. 02), the C4 component of
complement (P<. 05), C-reactive protein (CRP) (P<. 02),
and interleukin 6 (IL-6) (P<. 0005). Furthermore, a highly
signiﬁcantly decreased production of interleukin-2 (IL-2)
(P<. 0001) and tumor necrosis factor α (TNFα)( P<. 001)
in stimulated CD3+ lymphocytes and a decreased phagocy-
tosis of killed E. coli by polymorphonuclears (P<. 0001)
were observed. In spite of the frequency of these aberrations,
no consistent pattern which might be characteristic for CML
was revealed. In the subsequent follow-up we unfortunately
met considerable diﬃculties. First of all, we lost the majority
of patients (13 of 24) for various reasons. Several of them
were transplanted, a few moved out of Prague or even left the
country, and some simply lost their interest in participating
in the study. Another complication resulted from the dra-
maticprogressinthetherapyofCMLduetotheintroduction
of a new generation of highly eﬀective and relatively very
well-tolerated new drugs (see above). From ethical reasons,
it was necessary to substitute these new drugs for the older
ones. It followed that most of the patients were treated with
more than one drug.
2.MaterialsandMethods
2.1. Patients. The basic data on 11 patients enrolled at the
time of diagnosis (i.e., before starting any therapy) who
remained in the study throughout are shown in Table 1.
The group consisted of 5 males and 6 females, their
median age was 48 years, and their age range from 33 to
62 years. The follow-up lasted for 44 to 58 months. All
patients were treated either with imatinib mesylate (IM) or
dasatinib (DS), but not in all of them were these drugs used
as the starting therapy. In six patients, administration of
tyrosine-kinase inhibitors (TKI) was preceded by interferon
α (IFNα) treatment and in ﬁve patients the administration
of IFNα followed the initial treatment with hydroxyurea
(HU). In two patients, HU was given prior to IM treatment.
Hematological remission was achieved in all patients and
complete cytogenetic remission (CCR) was achieved in nine
of them in the course of the observation period. This was
associated with the decrease of lymphocyte count in nearly
all the patients. The only exception was patient no. 6, with
leukopenia prior to the start of the therapy, in whom the
remission was associated with an increase of lymphocyte
count up to the norm. At the end of the observation period,
thrombocyte count was below the level of 450 × 109/Li n
all patients. In eight of the patients the therapy was not
associated with any complication. Patient no. 1, who had
originally been treated with HU and who had developed
symptoms of immunodeﬁciency (neutropenia, aphthous
stomatitis, repeated infections of the upper and lower respi-
ratory tract) in the course of the observation period, under-
went a supportive therapy with growth factors (Neupogen
300μG/week) and immunoglobulins (Pasteurised Human
Immunoglobulin Grifols 16% 5mL i.m. once a week for
3 weeks). Moreover, erythematous eruptions diagnosed as
erythema nodosum vasculitis developed on her feet. As an
additional therapy, she received routine anti-inﬂammatory
drugs and local corticosteroids. In this patient CCR was not
achievedinspiteoftheIMdosehavingbeenraisedto600mg
per day.Clinical and Developmental Immunology 3
In patients nos. 6 and 7, laboratory tests revealed autoan-
tibodies against thyroidal peroxidase and thyreoglobulin
without clinical signs of hyper- or hypothyroidism. After
switching to IM or DS, the laboratory ﬁndings normalized
(see the Results section).
2.2. Drugs Used. Patients were treated as speciﬁed in Table 1.
LITALIR(HU—Hydroxycarbamidum500mg,Bristol-Myers
Sq uib b ,Lt d,P rague,C z ec hR epub lic),R OFER ON-A(INF -α-
Interferon α 2a 18MIU/0.6mL inj. sol., Roche, Ltd, Prague,
Czech Republic), Glivec (imatinib-mesylate Glivec, 478mg,
Novartis Europharm Ltd., Horsham, West Sussex, Great
Britain), and SPRYCEL (Dasatinib 100mg, Bristol-Myers
Squibb Pharma Eeig, Uxbridge Business Park, Sanderson
Road, Uxbridge, UK) were used. The dosage of the drugs
administered is indicated in Table 1.
2.3. Blood Samplings. Before sampling, written Informed
Consent was obtained from all patients and the study was
approved by the Ethical Committees of the institutions
concerned. In addition to samples taken for routine hemato-
logical and biochemical testing, materials for immunological
assays were obtained from each subject. The ﬁrst samples
were taken prior to the start of any therapy. Subsequent
samples were usually collected before the change in therapy.
The intervals varied (with one exception, patients no. 8)
from 6 to 30 months. The blood samples were distributed
into tubes purchased from BD Vacutainer Systems, Belliver
IndustrialEstate,Plymouth,UK,asfollows:(i)7mLofblood
were taken into Z tubes, coagulated, and the serum was
used for humoral immunity tests; (ii) 2mL of blood were
mixedwithEDTAforimmunophenotypicanalysis;(iii)2mL
of the whole blood were mixed with sodium heparine for
the measuring of intracellular cytokines. The materials were
tested (see below) immediately after arrival at the laboratory,
except the viral antibodies, CRP and IL-6 (see below) for
which all sera were tested simultaneously. Portions of the
materials were preserved for further tests. Sera were stored
at −20◦C and leukocyte suspensions were stored in liquid
nitrogen for possible future tests.
2.4. Immunoglobulins. The levels of the total IgG, of the IgG
subclasses, of IgA, and IgM were measured by nephelometry
as described previously [22]. The standard laboratory refer-
ential ranges are 6.9–14.0g/L for IgG, 4.9 –11.4g /L for IgG1,
1.5–6.4g/L for IgG2, 0.2–1.1g/L for IgG3, 0.08–1.4g/L for
IgG4, 0.7–3.7g/L for IgA, and 0.34–2.4g/L for IgM.
2.5. Autoantibodies. Antibodies against thyroidal peroxidase
(ATPOAb),thyreoglobulin(ATGAb),nucleus(ANAb),mito-
chondria (AMAb), smooth muscles (ASMAb), cytoplasm
of neutrophils (ANCAb), and endomysium (AE-GAb, AE-
AAb; G refers to IgG and A refers to IgA antibody,
resp.) were detected by indirect immunoﬂuorescence as
described previously [22]. We have also tested the presence
of antidesmosomal antibodies (ADESAb). Only the presence
or absence of antibodies was monitored, not their titers.
2.6. Complement. The levels of the C3 and C4 components
ofcomplementweremeasuredbynephelometryasdescribed
previously [22]. The standard laboratory referential ranges
are 0.75–1.4g/L for C3 and 0.10–0.34g/L for C4.
2.7. C-Reactive Protein. T h el e v e l so ft h eC - r e a c t i v ep r o t e i n
(CRP) were measured by nephelometry as described previ-
ously [22]. The standard laboratory reference range is 0.00–
5.0mg/L.
2.8. Interleukin-6. For the determination of interleukin 6
(IL-6), the quantitative sandwich enzyme immunoassay
techniques was used as described previously [22]. The
standard laboratory referential range is 3.13–12.5μg/L.
2.9. Subpopulations of Lymphocytes. Immunophenotypic
analysis of lymphocytes was performed using monoclonal
antibodies directed against the following human surface
antigens: CD3, CD4, CD8, CD19, CD16, and CD56 by ﬂow
cytometry as described previously [22]. The sum of cells
stained with CD4, CD8, CD19, and CD16-CD56 antibodies
was considered 100%. The standard laboratory referential
ranges are: 59%–84% for CD3+, 25%–59% for CD4+, 19%–
48% for CD8+, 6%–22% for CD19+, 6%–30% for CD16+,
CD56+ cells.
2.10. Intracellular Cytokine Production by Stimulated CD3+
Cells. Intracellular production of interleukin-2 (IL-2) inter-
leukin-4 (IL-4), tumor necrosis alpha (TNFα), and inter-
feron gamma (INFγ) in CD3+ cells stimulated by the mix-
ture of brefeldinA and phorbol-12-myristate-13-acetate was
monitored by ﬂow cytometry as described previously [22].
The ﬁgures shown in the Results section indicate the
percentages of CD3+ producing the individual cytokines.
2.11. Antibodies against Herpesviruses and Human Papillo-
maviruses. Antibodies were determined against the follow-
ing herpesviruses: the herpes simplex virus type 1 and type 2
(HSV 1 and 2, IgG and IgM), the varicella-zoster virus (VZV,
IgG and IgM), the human cytomegalovirus (CMV, IgG and
IgM) and the EB virus (EBV, IgG and IgM against the virus
capsid antigen [VCA], IgG against the virus nuclear antigen
[EBNA1] and against the early antigens [EA R+D]). The
following commercial kits were used: ETI-HSVK-G-1/2 and
ETI-HSVK-M-1/2 (DiaSorin S.p.A., Italy) for the detection
of HSV 1/2 IgG and IgM antibody, respectively; ETI-
CYTOK-G Plus and ETI-CYTOK-M REV Plus (DiaSorin
S.p.A., Italy ) for the detection of CMV IgG and IgM
antibody, respectively; VZV IgG and VZV IgM (Nova Tec,
Immunodiagnostica, GmbH Germany) for the detection of
V Z VI g Ga n dI g Ma n t i b o d y ,r e s p e c t i v e l y ;E T I - E B VV C A - G
and ETI-EBV-VCA-M-Rev (DiaSorin S.p.A., Italy) for the
d e t e c t i o no fE B VV C AI g Ga n dI g Ma n t i b o d y ,r e s p e c t i v e l y ;
ETI-EBNA-G (DiaSorin S.p.A., Italy) for the detection of
EBV EBNA IgG antibody; and ETI-EA-G (DiaSorin S.p.A.,
Italy) for the detection of EBV EA IgG antibody. In addition,
antibodies to six types of human papillomaviruses (HPV),
namely, types 6, 11, 16, 18, 31, and 33 were determined4 Clinical and Developmental Immunology
Table 1: Patients followed.
No. Gender Age1 Treatment Hematologic
Mo2 Drug Dosage/d WBC × 109/LL y m p h o × 109/LH b ( g r / L )T r c × 109/LH R 3 CCR3
(1) F 55
0 dg, HU 2000mg 302.6 4.60 89 413
19 No
8 IFN 5MIU 16.2 1.45 130 188
16 IFN 5MIU 69.0 3.43 131 442
22 IM 400mg 10.5 2.86 124 399
27 IM 400mg 7.4 1.93 120 505
39 IM 600mg 4.0 1.11 120 175
58 DS 100mg 2.1 0.89 119 139
(2) F 62
0 dg, HU 2500mg 120.0 3.54 132 226
61 9
6 IFN 3MIU 4.7 1.49 151 163
14 IFN 3MIU 5.1 1.20 131 352
15 IFN 5MIU 5.8 0.91 140 356
25 IM 400mg 3.2 1.12 138 157
43 IM 400mg 7.0 1.38 130 430
56 IM 400mg 9.3 1.61 130 648
(3) M 40
0 dg, HU 3000mg 21.9 2.07 168 327
82 6
7 IFN 3MIU 8.1 1.08 163 262
15 IFN 5MIU 3.1 0.85 160 125
26 IM 400mg 4.2 1.10 146 246
43 IM 400mg 4.5 1.37 147 209
58 IM 400mg 3.9 1.01 158 210
(4) M 60
0 dg, HU 2000mg 198.5 5.06 110 550
63 6
6 IFN 3MIU 3.4 0.86 132 115
12 IFN 5MIU 3.4 1.21 137 152
42 IM 400mg 5.5 1.52 131 301
56 IM 400mg 3.5 1.56 136 311
(5) M 33
0 dg, HU 2500mg 99.7 5.91 142 169
24 0
6 HU 2000mg 9.9 3.56 145 151
9 IFN 3MIU 47.8 3.12 137 102
40 IM 400mg 4.3 1.69 142 202
53 IM 400mg 5.5 2.01 140 258
58 IM 400mg 6.6 1.88 136 266
(6) F 35
0 dg, IFN 3MIU 107.5 0.48 117 276
23 5
10 IFN 3MIU 4.4 0.76 101 182
12 IM 400mg 2.8 1.12 102 145
36 DS 100mg 2.9 1.61 89 233
48 DS 100mg 2.8 1.83 89 331
(7) M 54
0 dg, HU 2000mg 16.4 4.86 136 595
11 38
7 HU 2000mg 4.5 5.71 137 532
20 HU 1000mg 5.5 3.21 134 209
34 IM 400mg 6.9 1.23 134 206
47 IM 400mg 6.8 2.19 132 236Clinical and Developmental Immunology 5
Table 1: Continued.
No. Gender Age1 Treatment Hematologic
Mo2 Drug Dosage/d WBC × 109/LL y m p h o × 109/LH b ( g r / L )T r c × 109/LH R 3 CCR3
(8) F 43
0 dg, IM 400mg 26.9 4.05 144 464
21 7
2 IM 400mg 8.3 1.66 129 228
9 IM 400mg 6.0 1.76 123 185
17 IM 400mg 7.5 1.26 126 207
31 IM 300mg 7.6 1.73 120 239
45 IM 300mg 8.3 1.45 125 315
(9) M 48
0 dg, IM 400mg 439.2 6.16 81 184
7N o 30 IM 400mg 4.4 1.96 150 117
44 IM 400mg 5.4 1.41 149 112
(10) F 38
0 dg, IM 400mg 328.6 1.81 88 614
52 7 7 IM 400mg 3.0 1.32 121 200
28 IM 400mg 3.3 1.10 94 212
36 IM 400mg 4.9 0.98 103 236
(11) F 61
0 dg,HU 2000mg 16.8 5.31 109 1895
42 5 29 DS 100mg 5.8 2.02 100 519
52 DS 100mg 5.4 2.75 104 249
1Age at enrollment; 2M o :m o n t h ;W B C :w h i t eb l o o dc e l lc o u n t ;H b :h e m o g l o b i n ;a n dT r c ,t h r o m b o c y t ec o u n t ;H U :h y d r o x y u r e a ;I F N :i n t e r f e r o n - a l p h a2 a ;
IM: imatinib mesylate; DS: dasatinib; MIU, Millions International Units. 3The ﬁgure indicates month after diagnosis at which HR or CCR was ﬁrst observed;
“no” means that CCR was not achieved.
Notes: Patient no. 1 developed vasculitis (erythema nodosum), neutropenia which was subsequently treated with growth factors and immunoglobulins.
Patients 6 and 7 had laboratory tests positive for autoimmune thyroiditis without any clinical manifestations.
Patient no. 11 decided to undergo homeopathic therapy and self-therapy with HU and was out of the evidence for some time. At the indicated interval, DS
therapy was started because of pathological ﬁndings both in peripheral blood and bone marrow.
using ELISA using virus-like particles as antigen as described
previously [23]. Sera were diluted according to correspond-
ing manufacturer recommendation, in case of anti-HPV
antibodies 1:25. All samples originating from the same
patient were tested simultaneously on one microplate.
2.12. Statistical Methods. In individual patients, Spear-
man’s correlation coeﬃcient was used for quantifying the
monotony of trend in time of the measured items. The
statistical diﬀerence P for the deviation from zero was
calculated. When analyzing the hematologic ﬁndings for the
whole group of patients, the data transformed to logarithms
were analyzed by covariance analysis testing for diﬀerences
among patients and the common linear regression onto the
time of treatment. The linear function was used as a basic
componentoftheexperiencedtimetrend.Forcomparisonof
the relative percentage distribution of diﬀerent lymphocyte
populations in the ﬁrst and last samples available, χ2 test
was used. For evaluation of the production of cytokines by
stimulated CD3+ cells, the mean ratio of the last and ﬁrst
samples available was tested by One Sample Student t-test
for diﬀerence from 1. P-values have not been adjusted for
multiple comparisons.
3. Results
3.1. Immunoglobulins Levels. The results of measuring the
immunoglobulins levels are summarized in Table 2.N e a r l y
generally, there was a tendency to a decrease of their levels.
The decrease of total IgG for the whole group was just on
the brink of statistical signiﬁcance (P = .05). In two patients
(nos. 2 and 7) the IgG levels dropped below the norm.
On the other hand, a marked increase of IgGs was observed
in one patient (No. 6, treated gradually with IFNα,I M
and DS) who had had the lowest level of total IgG and
pathologically low levels of IgG1, IgG2, IgG3 and IgG4 in
her pretreatment serum. The treatment resulted in their
restoration up to the norm. It may be of interest that in this
patient the hemoglobin level dropped in the course of the
observation period (see Table 1). The most frequent changes
were in the IgM levels. Their slight or moderate decrease was
observed in 9 patients and usually it was most marked after
treatment with IM. The decrease of IgM levels for the whole
group was signiﬁcant (P = .011). Changes in IgA levels were
seen less frequently. Its levels dropped signiﬁcantly with time
in only one patient (no. 2) and increased in other three (nos.
6,9and 11).Theﬁrstoneofthesewasthealreadymentioned
patient no. 6 with an increase in all subclasses of IgG. It
is noteworthy that throughout the observation period the
changes in this particular patient were not associated with
any marked variation in the IgM level.
3.2. Presence of Autoantibodies. The presence of autoanti-
bodies is shown in Table 3. Again, no consistent pattern is
apparent. Autoantibodies, which had been present in the
pretreatment sera of only three patients (twice against TPO6 Clinical and Developmental Immunology
Table 2: Imunoglobulins.
No. Therapy IgG IgG1 IgG2 IgG3 IgG4 IgA IgM
(1)
dg, HU 10.60 6.73 4.29 0.686 0.526 2.16 1.65
IFN 11.10 6.14 3.74 0.767 0.364 1.95 1.50
IFN 9.30 5.97 3.22 0.530 0.250 1.93 1.56
IM 12.30 8.90 3.99 0.709 0.119 2.74 1.91
IM 9.40 6.82 3.34 0.575 0.157 2.17 1.61
IM 11.30 6.14 4.21 0.687 0.193 2.92 1.54
DS 11.40 6.70 3.81 0.907 0.253 2.73 1.29
(2)
dg, HU 10.00 6.72 3.34 0.418 0.460 2.31 0.76
IFN 8.58 5.00 3.34 0.353 0.339 2.12 0.72
IFN 8.53 5.64 3.00 0.358 0.397 1.68 0.45
IFN 9.39 4.50 3.13 0.320 0.247 1.50 0.40
IM 8.49 4.41 2.75 0.292 0.259 1.59 0.33
IM 6.78 3.98 2.18 0.312 0.179 1.35 0.20
IM 6.41∗∗ 3.91∗∗ 2.24∗∗ 2.92∗∗ 1.52∗∗ 1.23∗∗ 0.23∗∗
(3)
dg, HU 10.00 6.41 3.03 0.225 0.079 1.79 1.44
IFN 9.19 5.83 2.74 0.196 0.082 1.66 0.83
IFN 10.80 6.33 3.28 0.239 0.058 1.74 0.87
IM 9.08 5.71 3.23 0.190 0.091 1.66 0.38
IM 8.72 5.04 2.68 0.248 0.083 1.73 0.54
IM 9.41 5.18∗ 3.35 0.213 0.065 1.78 0.47
(4)
dg, HU 11.60 7.79 3.94 0.666 0.833 1.86 0.94
IFN 13.00 8.44 4.05 0.686 0.303 1.62 1.18
IFN 13.60 10.40 3.34 0.637 0.270 1.80 0.98
IM 10.90 6.51 3.10 0.541 0.231 1.62 0.58
IM 10.90 6.98 3.34 0.613 0.209∗∗ 1.84 0.66
(5)
dg, HU 10.40 6.29 3.04 0.248 0.133 1.59 1.76
HU 10.20 7.40 3.03 0.158 0.066 1.98 1.20
IFN 9.35 6.20 2.97 0.195 0.142 1.61 1.31
IM 9.21 5.01 2.82 0.236 0.097 1.83 1.13
IM 9.81 5.33 3.16 0.226 0.082 1.93 1.12
IM 9.11∗ 6.77 2.62 0.605 0.081 1.95 1.06∗∗
(6)
dg, IFN 8.05 5.63 1.27 0.135 0.073 1.17 1.10
IFN 11.30 n.t.a n.t. n.t. n.t. 1.39 1.29
IM 12.00 n.t. n.t. n.t. n.t. 1.58 1.41
DS 17.90 12.70 1.75 0.611 0.152 2.07 0.79
DS 13.6∗ 11.20 2.17∗∗ 0.416 0.188∗∗ 2.26∗∗ 1.18
(7)
dg, HU 8.92 4.60 4.01 0.388 0.610 1.22 0.95
HU 8.79 4.45 3.95 0.337 0.797 1.30 0.76
HU 8.76 3.81 4.11 0.266 0.702 1.34 0.51
IM 6.08 2.89 2.72 0.262 0.507 0.99 0.32
IM 6.63∗ 31.4∗ 2.90 0.303 0.425 0.93 0.36∗
(8)
dg, IM 12.60 9.51 3.53 0.080 n.t. 1.49 0.97
IM 11.60 8.81 2.73 0.083 0.320 1.75 0.79
IM 12.20 7.43 2.74 0.087 0.276 1.84 0.57
IM 12.60 7.64 3.21 0.087 0.188 1.67 0.63
IM 12.60 9.30 3.26 0.094 0.432 1.94 0.74
IM 11.70 7.41 2.95 0.072 0.273 1.93 0.72Clinical and Developmental Immunology 7
Table 2: Continued.
No. Therapy IgG IgG1 IgG2 IgG3 IgG4 IgA IgM
(9)
dg, IM 10.60 7.58 3.41 0.523 0.697 1.31 1.11
IM 9.43 5.36 3.41 0.480 0.790 1.47 1.11
IM 9.53 5.90 3.95 0.479∗∗ 0.738 1.81∗∗ 1.32
(10)
dg, IM 13.50 8.46 4.93 0.231 2.180 1.04 1.61
IM 14.20 7.63 5.63 0.211 1.970 1.28 1.60
IM 12.10 7.49 4.49 0.262 1.200 1.04 1.39
IM 12.20 6.63∗∗ 4.51 0.232 1.340 1.15 1.41
(11)
dg, HU 12.00 6.21 5.66 0.231 0.146 0.88 0.67
DS 11.50 5.97 5.63 0.271 0.085 0.91 0.45
DS 12.40 8.12 3.50∗∗ 0.677∗∗ 0.080∗∗ 1.02∗∗ 0.32∗∗
an.t.: not tested.
∗P<. 05, ∗∗P<. 01P for trend with time.
and once against SM), were detected in the course of the
observation period in a total of eight patients. In most of
them, their appearance was transitory. In two patients (nos.
1 and 6, both of them were females), autoantibodies were
detected against three antigens: in two patients (nos. 4 and
7) against two antigens and in four patients (nos. 2, 3,
9 and 10) against one antigen only. The most frequently
detected autoantibodies were reactive with TPO, TG and
nucleus (in all instances in three patients). In two patients
antibodies reactive with SM were detected. In 1 of these
(patient no. 1), they were present in the pretreatment serum
sample, disappeared after starting the therapy with HU and
were not detected later on when HU was gradually replaced
by IFNα and IM. A similar phenomenon was seen in patient
no. 7, in whom the initial reactivity with TPO and TG
disappeared in the course of the therapy. Thus no consistent
pattern was evident and, because of the multiplicity of drugs
employed for individual patients, no clear dependence on
the therapy used was observed. It may be of interest that the
antibodies against mitochondria (AMAb) and endomysium
(E-AAb and E-GAb) were never detected.
There seems to be some, but not quite a consistent
correlation with the mode of therapy and the development
of autoantibodies. Autoantibodies were detected in ﬁve of
six patients treated with IFNα and in four out of ﬁve
patients treated with HU (all of them had later on been
treated with IFNα) but in only two out of four patients
exclusively treated by TKI (either IM or DS). Furthermore,
in four patients autoantibodies detected after HU and IFNα
treatment disappeared when these drugs were replaced by
IM.
3.3. Complement C3 and C4 Components. In the pretreat-
ment sera normal levels of C3 were observed in all but one
patient (no. 11), in whom the level was below the norm.
As indicated in Table 4, little variation of C3 levels was
observed in the course of the observation period; still, in
three patient’s a transitory decrease of its level below the
standard laboratory range was observed. In all instances
(including patient no. 11), their levels returned to the norm
by the time hematological remission was achieved. In two of
threepatientswiththeincreasedlevelsofC4inpre-treatment
sera (nos. 4, and 5), their levels dropped in the course of
treatment.
3.4. C-Reactive Protein and IL-6. The results are also
presented in Table 4. Prior to the start of the therapy,
increased levels of CRP were detected in six patients. Judging
by the levels detected in the last samples collected, the
levels dropped to the norm in all of them. However, it is
noteworthy that in two patients (nos. 3 and 8), in spite of the
hematological remission having been achieved, their levels
increased, and in four other patients (nos. 1, 2, 5 and 7)
a transitory increase of CRP was detected in the course of
the observation period. In patient no. 7 the increased level
of CRP corresponded with an acute infection of the upper
respiratory tract. In the other four patients (nos. 1, 3, 5 and
7) no clinical complications at the time of CRP increase were
observed or reported by the patients. As concerns IL-6 levels,
there was a nearly general decrease in association with the
hematological remission. The decrease for the whole group
was highly signiﬁcant (P = .001). Again, as in the previous
study [22], no clear correlation between IL-6 and CRP levels
was apparent.
3.5. Lymphocyte Subpopulations. As indicated in Table 5,
in spite of the drop of lymphocytes (shown in Table 1),
there was little variation in the percentage of CD3+ cells
in the course of the observation period, including patient
no. 6, in whom lymphopenia was detected in the pre-
treatment sample (see Table 1), and patient no. 10 with
CD3+ lymphocyte percentage slightly below the norm. The
only exception was patient no. 11, initially treated with HU
who after a rather long interval without any treatment was
treated with DS. In this patient a marked drop of CD3+
cells was detected. It is clear, however, that this decrease was
relative, reﬂecting a substantial increase of NK cells. The
changes in the percentages of CD4+ and CD8+ were slight
or moderate in nearly all patients and no consistent pattern8 Clinical and Developmental Immunology
Table 3: Autoantibodies.
No. Therapy TPOAb TGAb ANAb ANCAb AMAb ENDOAb A ENDOAb G SMAb DESMAb
(1)
dg, HU na nn n n n n pb n
IFN n n n p nn nn n
IFN n n n n n n n n p
IM n n n p nn nn p
IM n n n p nn nn p
IM n n n n n n n n p
DS n n n n n n n n p
(2)
dg, HU n n n n n n n n n
IFN n n n n n n n n n
IFN n n n n n n n n n
IFN n n p nn n n n n
IM n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
(3)
dg, HU n n n n n n n n n
IFN n n n n n n n n n
IFN n n n n n n n p n
IM n n n n n n n n n
IM n n n n n n n p n
IM n n n n n n n n n
(4)
dg, HU n n n n n n n n n
IFN n n n n n n n n n
IFN n n n n n n n n p
IM p nn n n n n n n
IM n n n n n n n n n
(5)
dg, HU n n n n n n n n n
HU n n n n n n n n n
IFN n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
(6)
dg, IFN p nn n n n n n n
IFN pp nnn n n n n
IM p n p nn n n n n
DS p nn n n n n n n
DS p nn n n n n n n
(7)
dg, HU pp nnn n n n n
HU pp nnn n n n n
HU n.t.c n.t. n n n n n n n
IM pn nnn n n n n
IM n n n n n n n n n
(8)
dg, IM n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
IM n.t. n.t. n n n n n n n
IM n n n n n n n n nClinical and Developmental Immunology 9
Table 3: Continued.
No. Therapy TPOAb TGAb ANAb ANCAb AMAb ENDOAb A ENDOAb G SMAb DESMAb
(9)
dg, IM n n n n n n n n n
IM n n n n n n n n n
IM n n n p nn nn n
(10)
dg, IM n n n n n n n n n
IM n n n n n n n n n
IM n n n n n n n n n
IM n n p nn n n n n
(11)
dg, HU n n n n n n n n n
DS n n n n n n n n n
DS n n n n n n n n n
TPOAb: antibodies against thyroidal peroxidase; TGAb: antibodies against thyreoglobulin; ANAb: antinuclear antibodies; ANCAb: antibodies against the
cytoplasm of neutrophils; AMAb: antimitochondrial antibodies; ENDOAb A, ENDOAb G: antibodies of the IgA and IgG classes against endomysium; SMAB:
antibodies against smooth muscless; DESMAb: antidesmosomal antibodies.
aNegative for the respective antibodies.
bPositive for the respective antibody.
cn.t.:not tested.
was evident. Still, in four of seven patients, in whose pre-
treatment samples the percentage of CD8 cells was below the
norm, their percentages did not reach the lower limit of the
referential range. In four patients (nos. 4, 5, 6 and 10) the
remission was associated with an increase in CD19+ cells.
When the distribution of lymphocyte subpopulations in the
ﬁrst and last sample was compared, signiﬁcant diﬀerences
(P<. 05to<. 001)wereencounteredinsixpatients(nos.1,3,
5, 6, 9 and 11). However, no consistent pattern was apparent
and thus the real signiﬁcance of these ﬁndings is doubtful.
3.6. Intracellular Production of Cytokines. The results are
presented in Table 6. Two observations may be of interest.
PossiblythemostimportantonewasanincreaseoftheCD3+
cells, which produce the cytokines, in most of the patients,
including those, in whom the production of these cytokines
prior to the start of the therapy had been pathologically low
(e.g., in the case of IL-2, patients nos. 3 and 8). Of the ten
patients, which could be evaluated, the percentage of IL-2-
producing cells increased in seven, IL-4-producing cells also
in seven, TNFα-producing cells in six and INFγ producing
cells in seven. In some of the patients the level of cytokine
production remained essentially unchanged (e.g., patient no.
8, all four cytokines) and in one patient there was a drop
of IL-2 and IL-4 production (patient no. 1) and in another
patient the drop of INFγ production (patient no. 2).
The other noteworthy observation, closely associated
with the ﬁrst one, was an increase in cells producing more
than one cytokine after stimulation, as reﬂected by an
increase of the percentage sum of reactive cells. The increase
was expressed in terms of the Cytokine Production Index
(CPI) given by the ratio between the sum of cytokine-
producing cells as detected in the last sample and the sum
of cytokine producing cells in the ﬁrst sample available (i.e.,
in all but one patient before the start of therapy). A marked
i n c r e a s ei nC P Iw a sd e t e c t e di ns e v e n( n o s .3 ,4 ,5 ,6 ,7 ,9
and 10) out of 10 patients which could be evaluated. The
diﬀerence for the group was highly signiﬁcant (P = .006).
3.7. Antibodies Against Herpesviruses and Papillomaviruses.
To clarify whether treatment of the CML patients with HU,
IFNα or TKI was associated with activation of latent and/or
persistent virus infections, we tested sera from the patients
for presence of antibodies against four human herpesviruses
andsixhumanpapillomaviruses.Theresultsaresummarized
in Tables 7 and 8. For the sake of simplicity, only the results
of testing sera taken prior to the start of any treatment and
at the end of the observation period are presented. It is
evident that there was only very little diﬀerence between the
two sets of sera. In one patient (no. 11) treated with DS,
cytomegalovirus infection was reactivated as revealed by a
very marked increase in IgG antibody and the appearance of
IgM antibody (results not shown).
4. Discussion
In the preceding paper [22], we showed that CML patients
before treatment diﬀered from matched healthy subjects in
a number of immunological parameters. The major aim
of the present investigation was to ﬁnd out, whether these
aberrationspersisted,decreased,ordisappearedinthecourse
of treatment, in particular whether these changes correlated
with the induction of hematological and/or cytogenetic
remission, whether and how they were inﬂuenced by the
drugsusedfortreatment,and,inthelongrun,whatwastheir
prognostic value, if any. Our eﬀorts were seriously hampered
by two circumstances, that is, by the loss of 13 out of 24
patients originally enrolled and, for ethical reasons, by the
impossibility to maintain the original treatment regimen10 Clinical and Developmental Immunology
Table 4: Complement components, CRP and IL-6.
No. Therapy C3 C4 CRP IL-6
(1)
dg, HU 0.94 0.40 5.2 5.10
IFN 0.67 0.37 3.0 2.53
IFN 0.83 0.42 24.4 5.42
IM 0.71 0.30 3.5 1.83
IM 0.53 0.21 3.5 1.53
IM 0.72 0.30 3.3 1.67
DS 1.26 0.52 3.2 2.72
(2)
dg, HU 1.24 0.30 12.8 9.54
IFN 1.22 0.28 3.0 3.47
IFN 1.22 0.28 3.5 3.87
IFN 1.15 0.25 3.5 4.92
IM 1.19 0.26 3.2 3.21
IM 1.27 0.27 5.4 2.45
IM 1.20 0.24∗ 3.2 2.82∗
(3)
dg, HU 1.19 0.26 3.0 3.9
IFN 1.14 0.26 3.0 1.8
IFN 0.94 0.24 3.5 1.5
IM 1.15 0.27 3.3 2.16
IM 1.20 0.26 3.2 1.14
IM 1.40 0.30 32.9 3.03
(4)
dg, HU 1.35 0.38 11.6 4.40
IFN 0.90 0.21 3.0 1.54
IFN 1.11 0.23 3.5 1.97
IM 1.20 0.27 3.2 1.45
IM 1.06 0.25 3.2 1.50
(5)
dg, HU 1.03 1.23 3.0 3.30
HU 0.97 0.21 3.5 3.67
IFN 0.80 0.20 3.5 2.16
IM 0.91 0.19 3.2 2.49
IM 1.14 0.23 8.8 2.30
IM 1.00 0.25 3.4 1.99
(6)
dg, IFN 0.98 0.21 3.0 2.80
IFN 0.69 0.19 n.t.a 1.82
IM 0.78 0.17 3.5 1.87
DS 1.31 0.30 3.2 2.31
DS 1.14 0.24 3.2 0.00
(7)
dg, HU 0.91 0.16 3.5 5.08
HU 0.68 0.15 3.5 4.24
HU 0.91 0.18 3.3 5.29
IM 0.91 0.19 21.3 1.82
IM 0.98 0.17 3.2 3.00
(8)
dg, IM 0.93 0.19 3.5 3.80
IM 0.94 0.19 3.8 2.63
IM 0.89 0.17 3.2 2.31
IM 0.89 0.18 3.3 1.53
IM 1.07 0.26 9.4 0.27
IM 1.11 0.33 6.1 1.70∗Clinical and Developmental Immunology 11
Table 4: Continued.
No. Therapy C3 C4 CRP IL-6
(9)
dg, IM 0.86 0.29 23.0 14.20
IM 0.91 0.24 3.2 1.21
IM 1.05∗∗ 0.27 3.2 1.00∗
(10)
dg, IM 0.79 0.30 5.9 16.71
IM 0.86 0.24 3.3 4.97
IM 0.81 0.17 3.2 n.t.
IM 0.76 0.17 3.2 1.00∗∗
(11)
dg, HU 0.65 0.36 6.8 5.20
DS 0.59 0.25 3.2 2.23
DS 0.80 0.35 3.4 3.50
an.t.:not tested.
∗P<. 05, ∗∗P<. 01P for trend with time.
with either HU or INFα. Because of the changes in the treat-
ment modalities, the original set of patients split into two
groups. The ﬁrst one consisted of eight patients originally
treated with HU and/or INFα and subsequently with TKI,
while the remaining three patients treated exclusively with
TKI constituted the second group.
Of these two shortcomings, the diminution of our set
of patients from 24 to 11 was certainly the more impor-
tant one. This reduction increased the diﬃculties already
inherent in the group studied, that is, its inhomogeneity
(age, sex, diﬀerent treatments), as regards evaluation of the
data obtained. Still, because in all patients hematological
remission and in nearly all of them even CCR was achieved,
this bringing an element of homogeneity into the study
group, some conclusions can be drawn. The most important
one is the nearly general association of the remission with
a normalization of the aberrant immunity parameters, both
humoral a cellular. One can assume that this normalization
was due to an alleviation of the CML-associated processes.
The continuing followup of the patients should reveal
whether any relapse of the disease would be associated with
deviations from the norm and with the reappearance of the
same or appearance of some other aberrations.
As regards the levels of immunoglobulins, there was a
tendency towards their decrease, predominantly IgM. The
gradual decrease of IgM levels was highly signiﬁcant. These
ﬁndings correspond with the results reported by Steegmann
et al. [24], who described considerable reduction of levels of
serum immunoglobulins, including IgM, in patients previ-
ously exposed to IFNα and then treated with IM; according
to their ﬁndings, the reduction of immunoglobulins was
especially marked in patients expressing a pronounced cyto-
genetic response. A marked selective eﬀect of IM treatment
on serum IgM level in one patient has been reported by
Nagasawa and Mizutan [25] .W ea r eu n a b l et op r o v i d ea n y
reasonable explanation for our observation. We can only
speculate that the decrease observed was due to qualitative
alteration of B cells by the therapy employed. Otherwise,
no consistent pattern was apparent. We only rarely detected
decreasein IgAlevels,whichwefoundsigniﬁcantlyincreased
in the pretreatment CML patients when compared with their
matched healthy controls [22].
When monitoring the presence of autoantibodies, we
detected them in ﬁve out of six patients treated with
INFα. These antibodies were directed against cytoplasm of
neutrophils (ANCAb), smooth muscles (ASMAb), nucleus
(ANAb), thyreoglobulin (ATG), or thyroidal peroxidase
(ATPO). This is not particularly surprising, since INFα
exhibits allo- and autostimulation activity on antigen pre-
senting cells. However, its activity in vivo may depend
on the simultaneous regulation of network of immune
cells rather than on the activation of individual popula-
tions [10]. INFα, but not IM, was reported to cause an
increased transcription of proteinase 3 in CD14-positive
monocytes, this suggesting another possible mechanism,
by which IFNα may promote self-antigen presentation [7].
In our study the appearance of autoantibodies was in most
instances of transitory character and that their disappear-
ance quite frequently followed the replacement of INFα
by IM. However, autoantibodies also developed in two
out of ﬁve patients untreated with INFα. It is therefore
diﬃcult to claim, on the basis of the present results, that
INFα was markedly more active than TKI in inducing
autoantibodies. It should be added that, in our patients, the
development of antibodies did not manifest itself in any
clinically recognizable disease, with the possible exception
of the simultaneous presence of ANCAb and vasculitis in
patient no. 1. This possible association and the subsequent
cure of the vasculitis in parallel with the disappearance of
the antibody after IM treatment seems to be in line with
ar e c e n tr e p o r t[ 26].
As concerns the C3 and C4 components of complement
there was little variation during the observation period.
Again, there was a tendency to normalization. This seems
to be in agreement with other ﬁndings in patients with
hematological malignancies including CML [27]; however,
the changes we observed were rather small and their signif-
icance is questionable. It seems clear that the follow-up of12 Clinical and Developmental Immunology
Table 5: Lymphocytes subpopulations.
No. Therapy CD3a CD4 CD8 CD19 CD3-CD16,56+
(1)
dg, HU 72 54 18 14 14
IFN 74 53 21 4 13
IFN 84 52 32 10 6
IM 76 48 28 11 12
IM 76 49 24 10 12
IM 73 47 26 13 10
DS 79 51 27 5 14
(2)
dg, HU 86 61 25 5 7
IFN 84 52 32 3 13
IFN 75 50 25 4 21
IFN 82 70 12 8 9
IM 69 54 15 11 20
IM 78 61 15 7 14
IM 80 62 15 7 13
(3)
dg, HU 76 39 37 12 12
IFN 79 42 36 8 13
IFN 73 44 29 13 13
IM 69 42 27 17 13
IM 72 48 24 15 13
IM 63 44 19 12 25
(4)
dg, HU 74 60 14 6 19
IFN 86 59 27 6 8
IFN 68 39 28 10 21
IM 75 52 23 13 12
IM 78 53 25 12 10
(5)
dg, HU 62 42 18 6 32
HU 66 43 23 20 14
IFN 62 40 22 24 14
IM 65 42 23 15 20
IM 66 41 20 13 20
IM 67 43 24 15 17
(6)
dg, IFN 83 40 43 10 6
IFN 77 53 23 11 11
IM 76 52 23 11 12
DS 76 31 43 11 12
DS 65 29 34 23 12
(7)
dg, HU 75 51 24 10 15
HU 81 54 27 7 12
HU 74 48 21 11 14
IM 73 52 20 12 14
IM 73 53 19 10 16
(8)
dg, IM 76 54 22 9 14
IM 72 55 17 13 16
IM 76 54 22 8 15
IM 77 55 19 10 11
IM 74 54 17 9 17
IM 74 57 17 12 14Clinical and Developmental Immunology 13
Table 5: Continued.
No. Therapy CD3a CD4 CD8 CD19 CD3-CD16,56+
(9)
dg, IM 85 29 53 3 12
IM 76 34 38 7 15
IM 74 37 34 9 15
(10)
dg, IM 67 52 14 14 16
IM 61 40 21 20 18
IM 55 37 16 18 25
IM 54 37 14 23 23
(11)
dg,HU 67 57 9 20 12
DS 59 49 9 16 23
DS 39 32 7 10 50
aThe ﬁgures indicate the percentages of cells positive for the respective surface CDs.
C3 and C4 components of complement was not particularly
rewarding in this study.
The results obtained when testing the CRP and IL-
6 levels are of greater interest. Both tended to decrease
following the therapy. The decrease was quite common in
the case of IL-6, where it was highly signiﬁcant. These
data suggest that a reduction of IL-6 levels might be quite
a reliable marker of successful therapy. Moreover, because
of its biological eﬀects, that is, inhibition of p53-induced
apoptosis [28] and suppression of phosphorylation of the
retinoblastoma protein [29], its drop might contribute
to the favorable course of the disease. Another favorable
eﬀect of IL-6 decrease might be associated with its role
in STAT-3 activation. High levels of STAT-3 can prevent
dendritic cell maturation and subsequent presentation of the
antigens [30]. Thus, increased levels of IL-6 might exhibit
an immunosuppressive eﬀect. In a way, the present data
correspond with the earlier observations indicating that IL-6
levels are raised in parallel with the progression of the disease
into blastic phase [31, 32]. An association of remission with
a decrease of CRP levels was less consistent. Although CRP
levels dropped in all patients with increased levels detected
in their sera taken prior to the start of the therapy, in four
other patients a CRP increase was observed in the course of
the observation period; in two of them it was only transitory.
Because of the nature of this acute phase reactant [33–35],
it is rather diﬃcult to interpret the latter ﬁndings. In one of
the patient the transitional rise of CRP was associated with
a respiratory disease. In the other patients some undetected
microinﬂammation processes might have been involved.
Possibly the most important among our ﬁndings are the
changes of cell-mediated immunity parameters associated
with the achievement of remission. They were represented
by a markedly increased capability of stimulated CD3+ cells
to produce cytokines. Since at the time of remission, the
sum of percentages of CD3+ cells producing any of the
cytokines tested exceeded 100 in most of the patients, it is
possible to conclude that the changes observed were mainly
duetoanincreaseincellsproducingmorethanonecytokine.
Thus, a restoration of the Tcell activities associated with the
suppression of the disease was observed. Similar results were
reported by Reuben et al. [36]. and Guarini et al. [37]. in
patients, in whom hematologic remission was achieved by
INFαtreatment.Themechanismsresponsibleforthepresent
ﬁndings are not quite clear. In this respect, two previous in
vitrostudies may be of interest and provide a lead for further
studies. Pawelec et al. [38]. have reported the production of
the immunosuppressive IL-10 cytokine, a potent inhibitor of
type 1 cytokines, by CML cells cultivated in vitro and have
demonstratedthatitsneutralizationbymonoclonalantibody
considerably enhanced the proliferation of lymphocytes in
mixed lymphocyte/tumor cell cultures [38]. In another
study, Kiani et al. [39]. Showed that CD4+ cells from CML
patients, which had been separated from the leukemic cells,
after stimulation produced type 1 cytokines in amounts
comparable to those seen in normal subjects. Taken together,
these two sets of data suggest that the products of CML
cellsmaythemselvesberesponsibleforthereducedimmuno-
competence of the CD3+ cells. One point deserves a special
comment. All ten patients, in whom the respective data were
available, had been treated, at least for some time, with
IM. This drug has been reported to suppress CD3+ cell
activationinvitro[40,41]aswellasotherparametersofTcell
immunity in vivo [42–44]. Our ﬁndings in the present study
donotseemtobeinagreementwiththoseobservations.One
can therefore hypothesize that the alleviation of the CML-
associated processes, which was induced by the successful
therapy, was a more important factor than the puta-
tive immunosuppressive eﬀect of IM. Furthermore, it has
recently been reported that IM is suppressing the activation
and proliferation of CD4+CD25+ regulatory cells (Treg cells)
which are producing strong immunosuppressive factors like
IL-10, transforming growth factor β (TGFβ)a n dg r a n z y m e
B[ 45]. It is thus very well possible that in the patients
studied the IM-induced suppression of Treg contributed to
the present observation. Unfortunately, we did not monitor
the levels of Treg cells in the present study. It should also
be recalled that a signiﬁcant increase of INFγ-producing
Tcells following IM treatment has been reported by
Aswald et al. [46].14 Clinical and Developmental Immunology
Table 6: Intracellular cytokines production in activated CD3+ lymphocytes.
No. Therapy IL-2 TNFalfa INF-γ IL-4 CPI
(1)
dg, HU 56 44 12 4
IFN 42 49 18 3
IFN 31 35 23 5
IM 53 60 30 2
IM 61 48 36 3
IM n.t.a n.t. n.t. n.t.
DS 32 60 23∗ 1 1.000
(2)
dg, HU 31 53 62 2
IFN 10 23 29 5
IFN 69 66 30 4
IFN 76 65 32 5
IM 67 73 42 6
IM n.t. n.t. n.t. n.t.
IM 55 45 35 20∗ 1.047
(3)
dg, HU 1 54 41 6
IFN 24 46 36 3
IFN 48 66 50 3
IM 23 51 25 1
IM n.t. n.t. n.t. n.t.
IM 49 57 51 20 1.735
(4)
dg, HU 17 20 25 6
IFN 31 46 29 8
IFN 38 78 38 6
IM n.t. n.t. n.t. n.t.
IM 56∗∗ 65 44∗∗ 11 2.588
(5)
dg, HU 22 21 14 4
HU 50 55 25 4
IFN 39 50 30 2
IM 37 49 24 8
IM 52 58 30 2
IM 38 41 30 5 1.869
(6)
dg, IFN 11 17 22 2
IFN 36 51 32 3
IM 48 55 35 5
DS 20 59 45 3
DS 18 44 37∗ 19 2.269
(7)
dg, HU 51 46 34 3
HU 52 42 30 2
HU 52 68 55 5
IM n.t. n.t. n.t. n.t.
IM 52 53 34 25 1.223
(8)
dg, IM 42 44 23 2
IM 38 44 19 2
IM 16 25 13 5
IM n.t. n.t. n.t. n.t.
IM n.t. n.t. n.t. n.t.
IM 41 37 23 3 0.937
(9)
dg, IM 2 34 45 1
IM n.t. n.t. n.t. n.t.
IM 31 74 57 13 2.134Clinical and Developmental Immunology 15
Table 6: Continued.
No. Therapy IL-2 TNFalfa INF-γ IL-4 CPI
(10)
dg, IM n.t. n.t. n.t. n.t.
IM 27 32 14 1
IM 38 54 24 3
IM 50∗∗ 51 30∗∗ 6∗∗ 1.827
(11)
dg, HU n.t. n.t. n.t. n.t.
DS 59 62 23 1
DS n.t. n.t. n.t. n.t. n.t.
CPI:Cytokine Production Index—a ratio between the sum of cytokine producing cells ls as detected in the last sample and the sum of cytokine producing
cells in the ﬁrst sample available.
an.t.:not tested.
∗P<. 05, ∗∗P<. 01.Pfor trend with time.
Table 7: Presence and geometric mean titres of antibodies against human herpesviruses in CML patients prior to the start of the therapy
and after achieiving hematological and/or complete cytogenetic remission.
Antibody presence
Sample No. HSV1/2 CMV VZV EBV
IgG IgM IgG IgM IgG IgM VCAIgG VCAIgM EAIgG EBNA IgM
First 11 11 2 8 0 11 2 11 2 3 10
Last 11 11 0 8 1 11 2 11 2 3 10
GMT
First 11 8.12 0.65 1.83 0.47 2.83 0.74 7.41 0.33 0.57 4.28
Last 11 8.33 0.57 2.01 0.47 2.61 0.54 8.20 0.34 0.65 4.79
Table 8: Presence and geometric mean titres of antibodies against human papillomaviruses in CML patients prior to the start of the therapy
and after achieving hematological and/or complete cytogenetic remission.
Antibody presence
Sample No. HPV6 HPV11 HPV16 HPV18 HPV31 HPV33
F i r s t 1 1 6 53331
L a s t 1 1 5 33321
GMT
First 11 1.27 1.01 0.68 1.00 0.79 0.50
Last 11 1.08 0.88 0.65 0.75 0.61 0.38
Our attempts to ﬁnd a reﬂection of these changes in the
antibody titers against herpesviruses and papillomaviruses,
two virus families known to be activated under immunosup-
pression, failed completely. As indicated in a previous paper
[22],therewerenosigniﬁcantdiﬀerencesintheprevalenceof
antibodies against these viruses between the untreated CML
patients and matched normal control subjects. In the present
study the antibody patterns in sera taken before the start
of therapy and after achieving remission were comparable,
this strongly suggesting that in the course of the observation
period the activation of latent infections did not occur or
could not be revealed by the antibody tests used.
In spite of inconsistency of the treatment regimens
described above, some diﬀerences in the changes of the
immunological parameters studied, which might have been
associated with the drugs used, were recorded. Two obser-
vations are noteworthy. First, the autoantibodies were more
frequently seen in patients who had been treated with HU
andINFαthaninthosetreatedexclusivelywithTKI,andthey
tended to disappear after substituting TKI for HU and INFα.
Still, the lackof consistency and the smallnumber of patients
tested preclude any conclusions. Second, increase of NK cells
was detected more frequently in those exclusively treated
with TKI than in patients who had undergone combined
therapy.
5. Conclusions
The present results indicate that the altered parameters of
innate immunity found in the CML patients prior to the
start of any therapy tended to normalize in the course of
therapy leading to remission. Other data suggested, but did
not prove, that some of the parameters monitored might be
inﬂuenced by the treatment modality used.16 Clinical and Developmental Immunology
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